ZYME Average Annual Return Since 2017
Growth of $10,000.00
Without Dividends Reinvested Into ZYME


Also see:
ZYME stock yearly return 2018
ZYME stock yearly return 2019
ZYME stock yearly return 2020
ZYME stock yearly return 2021
ZYME stock yearly return 2022
ZYME stock yearly return 2023
ZYME YTD return
Compare ZYME average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 05/01/2017
End date: 06/24/2024
Start price/share: $13.07
End price/share: $8.40
Dividends collected/share: $0.00
Total return: -35.73%
ZYME Average Annual Return: -5.99%
Starting investment: $10,000.00
Ending investment: $6,428.40
Years: 7.15


ZYME average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Zymeworks is a clinical-stage biopharmaceutical company focused on the development of multifunctional biotherapeutics. Co.'s primary product candidate, zanidatamab, is a bispecific (dual-targeting) antibody that targets two domains of the human epidermal growth factor receptor 2. Co.'s second product candidate, ZW49, combines the design of zanidatamab with its ZymeLink antibody-drug conjugate platform, comprised of its proprietary cytotoxin (cancer cell-killing compound) and cleavable linker. Co. is also developing a pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas. The ZYME average annual return since 2017 is shown above.

The Average Annual Return on the ZYME average annual return since 2017 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether ZYME average annual return since 2017 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the ZYME average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree ZYME Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Zymeworks (ZYME) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

ZYXI Average Annual Return
A Average Annual Return
AADI Average Annual Return
ABBV Average Annual Return
ABEO Average Annual Return
ABIO Average Annual Return
ABOS Average Annual Return
ABSI Average Annual Return
ABT Average Annual Return
ABVC Average Annual Return
More Healthcare companies »

 

ZYME Average Annual Return Since 2017 | www.AverageAnnualReturn.com | Copyright © 2021 - 2024, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.